Latest News for: 1022

Edit

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research ...

The Eagle-Tribune 26 Mar 2025
-- Abstract accepted for late-breaking poster presentation – ... .
Edit

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

PR Newswire 25 Mar 2025
-- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- ... We look forward to advancing EO-1022 into clinical development next year." ... About EO-1022.
Edit

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options

Victoria Advocate 20 Mar 2025
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- ....
Edit

Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options (Form 8-K) (Elevation Oncology Inc)

Public Technologies 20 Mar 2025
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options ... We are leveraging our ADC expertise to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors.
Edit

NNR ֍ EP. 1022 ֍ GUEST: GERMAR RUDOLF

Rumble 15 Mar 2025
Click the Rumble article link to see the video ....
  • 1

Article Search

tools
×
×
×
×